Related Experiment Video
Updated: Aug 5, 2026
11:00
Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment
Published on: March 25, 2020
Spatial multiomics to inform immunocytokine engineering: knowledge base, gaps, and QC solutions
Priyank Patel1, Luke Daniel Batty1, Marina Bleck1
1Immunology & Respiratory, Boehringer Ingelheim Ridgefield CT USA, Ridgefield, CT, United States.
Frontiers in Immunology
|July 30, 2026
Summary
Immunocytokines offer targeted cancer therapy by delivering cytokines directly to tumors, improving efficacy and reducing toxicity compared to systemic therapies. Advances in spatial-omics and improved sample handling are key to developing next-generation immunocytokines for better patient outcomes.
Area of Science:
- Immunotherapy
- Cancer Research
- Biotechnology
Background:
- Systemic cytokine therapies (e.g., IL-2) show promise but suffer from low response rates and severe toxicity.
- Immunocytokines deliver cytokines directly to tumors, reducing systemic side effects and enhancing anti-tumor activity.
- Spatial-omics technologies offer deep insights into the tumor microenvironment (TME) for target identification.
Purpose of the Study:
- To highlight the advantages of immunocytokines over systemic cytokine therapies.
- To discuss the role of spatial-omics in understanding the TME and developing novel immunocytokines.
- To address challenges in spatial-omics data analysis and propose solutions for improved immunocytokine design.
Main Methods:
- Review of current immunotherapy approaches, including systemic cytokines and immunocytokines.
- Discussion of spatial-omics techniques for TME analysis.
- Exploration of data processing and interpretation challenges in spatial-omics.
- Integration of TME knowledge with cytokine payload design.
Main Results:
- Immunocytokines demonstrate improved tumor targeting and reduced systemic toxicity compared to traditional cytokine therapies.
- Spatial-omics data can identify druggable targets and inform the development of novel antibody-cytokine platforms.
- Variability in sample quality and platform differences pose challenges to data integrity and niche identification.
Conclusions:
- Improving sample collection and processing is crucial for reliable spatial-omics data.
- Standardizing preprocessing workflows and developing consensus on niche identification are needed for reproducibility.
- Combining TME insights with autoimmune-derived cytokine knowledge can lead to innovative immunocytokines with enhanced targeting and effectiveness, improving patient outcomes.
